Vascular remodeling in hypertension

Hypertension: Principles and Practice

Volumn , Issue , 2005, Pages 85-98

  Humar, Rok ^a   Resink, Therese ^a   Battegay, Edouard J ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33947174954     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (91)

1. Scheirer J. Angiogenesis and vascular remodeling in the microvasculature. NIH guide 1995; 24.
2. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994; 330:1431-1438.
3. Mulvany MJ. Vascular remodelling of resistance vessels:can we define this? Cardiovasc Res 1999; 41:9-13.
4. Owens GK. Control of hypertrophic versus hyperplastic growth of vascular smooth muscle cells. Am J Physiol 1989; 257:H1755-H1765.
5. Greene AS, Tonellato PJ, Lui J, Lombard JH, Cowley AW, Jr. Microvascular rarefaction and tissue vascular resistance in hypertension. Am J Physiol 1989; 256:H126-H131.
6. Mulvany M. Resistance vessels in hypertension. Textbook of Hypertension. Oxford: Blackwell Science 1994.
7. Baumbach GL, Heistad DD. Remodeling of cerebral arterioles in chronic hypertension. Hypertension 1989; 13:968-972.
8. Mulvany MJ, Baumbach GL, Aalkjaer C et al. Vascular remodeling. Hypertension 1996; 28:505-506.
9. Schiffrin EL, Hayoz D. How to assess vascular remodelling in small and medium-sized muscular arteries in humans. J Hypertens 1997; 15:571-584.
10. Zervoudaki A, Toutouzas P. Remodeling of resistance vessels in essential hypertension. Hellenic J Cardiol 2003; 44:116-124.
11. Nordborg C, Ivarsson H, Johansson BB, Stage L. Morphometric study of mesenteric and renal arteries in spontaneously hypertensive rats. J Hypertens 1983; 1:333-338.
12. Short D. The vascular fault in chronic hypertension with particular reference to the role of medial hypertrophy. Lancet 1966; 1:1302-1304.
13. Korsgaard N, Aalkjaer C, Heagerty AM, Izzard AS, Mulvany MJ. Histology of subcutaneous small arteries from patients with essential hypertension. Hypertension 1993; 22:523-526.
14. Rosei EA, Rizzoni D, Castellano M et al. Media/lumen ratio in human small resistance arteries is related to forearm minimal vascular resistance. J Hypertens 1995; 13:341-347.
15. Rizzoni D, Porteri E, Castellano M et al. Vascular hypertrophy and remodeling in secondary hypertension. Hypertension 1996; 28:785-790.
16. Skov K, Mulvany MJ, Korsgaard N. Morphology of renal afferent arterioles in spontaneously hypertensive rats. Hypertension 1992; 20:821-827.
17. Pourageaud F, De Mey JG. Structural properties of rat mesenteric small arteries after 4-wk exposure to elevated or reduced blood flow. Am J Physiol 1997; 273:H1699-H1706.
18. Thybo NK, Stephens N, Cooper A, Aalkjaer C, Heagerty AM, Mulvany MJ. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995; 25:474-481.
19. Skov K, Fenger-Gron J, Mulvany MJ. Effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist, and an endothelin receptor antagonist on renal afferent arteriolar structure. Hypertension 1996; 28:464-471.
20. Thybo NK, Korsgaard N, Eriksen S, Christensen KL, Mulvany MJ. Dose-dependent effects of perindopril on blood pressure and small-artery structure. Hypertension 1994; 23:659-666.
21. le Noble FA, Stassen FR, Hacking WJ, Struijker Boudier HA. Angiogenesis and hypertension. J Hypertens 1998; 16:1563-1572.
22. Kiefer FN, Neysari S, Humar R, Li W, Munk VC, Battegay EJ. Hypertension and angiogenesis. Curr Pharm Des 2003; 9:1733-1744.
23. Tomanek RJ, Schalk KA, Marcus ML, Harrison DG. Coronary angiogenesis during long-term hypertension and left ventricular hypertrophy in dogs. Circ Res 1989; 65:352-359.
24. Vicaut E. Hypertension and the microcirculation: a brief overvierw of experimental studies. J Hypertens 1992; 10:S59-S68.
25. Levy BI, Ambrosio G, Pries AR, Struijker-Boudier HA. Microcirculation in hypertension: a new target for treatment? Circulation 2001; 104:735-740.
26. Risau W. Mechanisms of angiogenesis. Nature 1997; 386:671-674.
27. Flamme I, Frolich T, Risau W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J Cell Physiol 1997; 173:206-210.
28. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992; 90:456-461.
29. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R. TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 1990; 63:515-524.
30. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 1993; 91:2268-2274.
31. Azizi M, Boutouyrie P, Bissery A, Agharazii M, Verbeke F, Stern N, Bura-Riviere A, Laurent S, Alhenc-Gelas F, Jeunemaitre X. Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. J Clin Invest 2005; 115(3):780-787.
32. Carretero OA. Vascular remodeling and the kallikrein-kinin system. J Clin Invest 2005; 115(3):588-591.
33. Jin ZG, Ueba H, Tanimoto T, Lungu AO, Frame MD, Berk BC. Ligand-independent activation of vascular endothelial growth factor receptor 2 by fluid shear stress regulates activation of endothelial nitric oxide synthase. Circ Res 2003; 93:354-363.
34. Davies PF, Tripathi SC. Mechanical stress mechanisms and the cell. An endothelial paradigm. Circ Res 1993; 72:239-245.
35. Olesen SP, Clapham DE, Davies PF. Haemodynamic shear stress activates a K+ current in vascular endothelial cells. Nature 1988; 331:168-170.
36. Nakache M, Gaub HE. Hydrodynamic hyperpolarization of endothelial cells. Proc Natl Acad Sci USA 1988; 85:1841-1843.
37. Shen J, Luscinskas FW, Connolly A, Dewey CF Jr, Gimbrone MA Jr. Fluid shear stress modulates cytosolic free calcium in vascular endothelial cells. Am J Physiol 1992; 262:C384-C390.
38. Cooke JP, Rossitch E Jr, Andon NA, Loscalzo J, Dzau VJ. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. J Clin Invest 1991; 88:1663-1671.
39. Frangos JA, Eskin SG, McIntire LV, Ives CL. Flow effects on prostacyclin production by cultured human endothelial cells. Science 1985; 227:1477-1479.
40. Kuchan MJ, Frangos JA. Shear stress regulates endothelin-1 release via protein kinase C and cGMP in cultured endothelial cells. Am J Physiol 1993; 264:H150-H156.
41. Nishida K, Harrison DG, Navas JP et al. Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. J Clin Invest 1992; 90:2092-2096.
42. Resnick N, Collins T, Atkinson W, Bonthron DT, Dewey CF Jr, Gimbrone MA Jr. Platelet-derived growth factor B chain promoter contains a cis-acting fluid shearstress- responsive element. Proc Natl Acad Sci USA 1993; 90:4591-4595.
43. Ohno M, Cooke JP, Dzau VJ, Gibbons GH. Fluid shear stress induces endothelial transforming growth factor beta-1 transcription and production. Modulation by potassium channel blockade. J Clin Invest 1995; 95:1363-1369.
44. Chen-Konak L, Guetta-Shubin Y, Yahav H et al. Transcriptional and post-translation regulation of the Tie1 receptor by fluid shear stress changes in vascular endothelial cells. FASEB J 2003; 17:2121-2123.
45. Chen BP, Li YS, Zhao Y et al. DNA microarray analysis of gene expression in endothelial cells in response to 24-h shear stress. Physiol Genomics 2001; 7:55-63.
46. Loirand G, Rolli-Derkinderen M, Pacaud P. RhoA and resistance artery remodeling. Am J Physiol Heart Circ Physiol 2005; 288(3):H1051-H1056.
47. Tzima E, del Pozo MA, Shattil SJ, Chien S, Schwartz MA. Activation of integrins in endothelial cells by fluid shear stress mediates Rho-dependent cytoskeletal alignment. EMBO J 2001; 20:4639-4647.
48. Li S, Chen BP, Azuma N et al. Distinct roles for the small GTPases Cdc42 and Rho in endothelial responses to shear stress. J Clin Invest 1999; 103:1141-1150.
49. Wojciak-Stothard B, Ridley AJ. Shear stress-induced endothelial cell polarization is mediated by Rho and Rac but not Cdc42 or PI 3-kinases. J Cell Biol 2003; 161:429-439.
50. Shyy JY, Chien S. Role of integrins in endothelial mechanosensing of shear stress. Circ Res 2002; 91:769-775.
51. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension:roles of apoptosis, inflammation, and fibrosis. Hypertension 2001; 38:581-587.
52. Ueno H, Kanellakis P, Agrotis A, Bobik A. Blood flow regulates the development of vascular hypertrophy, smooth muscle cell proliferation, and endothelial cell nitric oxide synthase in hypertension. Hypertension 2000; 36:89-96.
53. Intengan HD, Deng LY, Li JS, Schiffrin EL. Mechanics and composition of human subcutaneous resistance arteries in essential hypertension. Hypertension 1999; 33:569-574.
54. Intengan HD, Thibault G, Li JS, Schiffrin EL. Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats: effects of angiotensin receptor antagonism and converting enzyme inhibition. Circulation 1999; 100:2267-2275.
55. Hu WY, Fukuda N, Ikeda Y et al. Human-derived vascular smooth muscle cells produce angiotensin II by changing to the synthetic phenotype. J Cell Physiol 2003; 196:284-292.
56. Thyberg J. Phenotypic modulation of smooth muscle cells during formation of neointimal thickenings following vascular injury. Histol Histopathol 1998; 13:871-891.
57. Turley EA. Extracellular matrix remodeling: multiple paradigms in vascular disease. Circ Res 2001; 88:2-4.
58. Eguchi S, Dempsey PJ, Frank GD, Motley ED, Inagami T. Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem 2001; 276:7957-7962.
59. Yamakawa T, Tanaka S, Kamei J, Kadonosono K, Okuda K. Phosphatidylinositol 3-kinase in angiotensin II-induced hypertrophy of vascular smooth muscle cells. Eur J Pharmacol 2003; 478:39-46.
60. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 2002; 16:1472-1487.
61. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T, Izumo S. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004.
62. Le Noble JLML, Tangelder GJ, Slaaf DW, van Essen H, Reneman RS, Struyker-Boudier HA. A functional morphometric study of the cremaster muscle microcirculation in young spontaneously hypertensive rats. J Hypertens 1990; 8:741-748.
63. Rizzoni D, Castellano M, Porteri E, Bettoni G, Muiesan ML, Agabiti-Rosei E. Vascular structural and functional alterations before and after the development of hypertension in SHR. Am J Hypertens 1994; 7:193-200.
64. Norrelund H, Christensen KL, Samani NJ, Kimber P, Mulvany MJ, Korsgaard N. Early narrowed afferent arteriole is a contributor to the development of hypertension. Hypertension 1994; 24:301-308.
65. Noon JP, Walker BR, Webb DJ et al. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest 1997; 99:1873-1879.
66. Antonios TF, Rattray FM, Singer DR, Markandu ND, Mortimer PS, MacGregor GA. Rarefaction of skin capillaries in normotensive offspring of individuals with essential hypertension. Heart 2003; 89:175-178.
67. Kiefer FN, Misteli H, Kalak N et al. Inhibition of nitric oxide biosynthesis, but not elevated blood pressure, reduces angiogenesis in rat models of secondary hypertension. Blood Press 2002; 11:116-124.
68. Levy BI, Duriez M, Samuel JL. Coronary microvasculature alteration in hypertensive rats. Effect of treatment with a diuretic and an ACE inhibitor. Am J Hypertens 2001; 14:7-13.
69. Ruilope LM, Alcazar JM, Rodicio JL. Renal consequences of arterial hypertension. J Hypertens Suppl 1992; 10:S85-S90.
70. Strauer BE. Significance of coronary circulation in hypertensive heart disease for development and prevention of heart failure. Am J Cardiol 1990; 65:34G-41G.
71. Motz W, Vogt M, Strauer BE. Coronary microcirculation in hypertensive heart disease: functional significance and therapeutic implications. Clin Invest 1993; 71:S42-S45.
72. Strauer BE. Left ventricular hypertrophy, myocardial blood flow and coronary flow reserve. Cardiology 1992; 81:274-282.
73. Rizzoni D, Porteri E, Guefi D et al. Cellular hypertrophy in subcutaneous small arteries of patients with renovascular hypertension. Hypertension 2000; 35:931-935.
74. Anderson WP, Kett MM, Stevenson KM, Edgley AJ, Denton KM, Fitzgerald SM. Renovascular hypertension:structural changes in the renal vasculature. Hypertension 2000; 36:648-652.
75. Ciuffetti G, Pasqualini L, Pirro M et al. Blood rheology in men with essential hypertension and capillary rarefaction. J Hum Hypertens 2002; 16:533-537.
76. Schiffrin EL. Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am J Hypertens 2004; 17(12 Pt 1):1192-1200.
77. Schiffrin EL. Vascular protection with newer antihypertensive agents. J Hypertens Suppl 1998; 16:S25-S29.
78. Schwartzkopff B, Brehm M, Mundhenke M, Strauer BE. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension 2000; 36:220-225.
79. Thurmann PA, Stephens N, Heagerty AM, Kenedi P, Weidinger G, Rietbrock N. Influence of isradipine and spirapril on left ventricular hypertrophy and resistance arteries. Hypertension 1996; 28:450-456.
80. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101:1653-1659.
81. Busse R, Fleming I, Hecker M. Signal transduction in endothelium-dependent vasodilatation. Eur Heart J 1993; 14(suppl I):2-9.
82. Hayashi I, Amano H, Yoshida S et al. Suppressed angiogenesis in kininogen-deficiencies. Lab Invest 2002; 82:871-880.
83. Miura S, Matsuo Y, Saku K. Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells. Hypertension 2003; 41:1118-1123.
84. Silvestre JS, Bergaya S, Tamarat R, Duriez M, Boulanger CM, Levy BI. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res 2001; 89:678-683.
85. Thuringer D, Maulon L, Frelin C. Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells. J Biol Chem 2002; 277:2028-2032.
86. Fabre JE, Rivard A, Magner M, Silver M, Isner JM. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 1999; 99:3043-3049.
87. Olivetti G, Cigola E, Lagrasta C et al. Spirapril prevents left ventricular hypertrophy, decreases myocardial damage and promotes angiogenesis in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1993; 21:362-370.
88. Mulvany MJ, Aalkjaer C. Structure and function of small arteries. Physiol Rev 1990; 70:921-961.
89. Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991; 22:339-347.
90. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3:401-410.
91. Sato Y. Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy. Int J Clin Oncol 2003; 8:200-206.